Low|dose atropine eyedrops no better than placebo for slowing ...

Low-dose atropine eyedrops no better than placebo for slowing ...

Low-dose atropine eyedrops no better than placebo for slowing myopia progression. NIH-funded trial underscores need for more research to head off high myopia.

Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control

We found that nightly low-dose atropine, 0.01%, eye drops did not slow myopia progression or axial elongation when compared with placebo over 24 ...

Low-Dose Atropine Eye Drops No Better than Placebo for Myopia

Use of low-dose atropine eyedrops (concentration 0.01%) was no better than placebo at slowing myopia (nearsightedness) progression and elongation of the eye.

Atropine 0.01% Eye Drops Did Not Slow Myopia Progression ...

After 24 months, mean changes in SE vs baseline were nearly identical for the atropine and placebo groups (−0.82 D vs −0.80 D, respectively).

Low-dose atropine eyedrops not effective in slowing myopia ...

... use of low-dose atropine eyedrops, commonly used in a higher dose to treat lazy eye, was no better than a placebo at slowing myopia ...

Study Finds Low-dose Atropine Ineffective vs. Myopia

An OD-MD group of researchers from the Pediatric Eye Disease Investigator Group tested atropine 0.01% against placebo for slowing myopia in U.S. ...

Performance of low dose atropine in US children? | Myopia Profile

Low-dose atropine was found to be no more effective in controlling myopia for US children than a placebo. ... Atropine Eye Drops vs Placebo ...

Nearsighted progression in children is not slowed by very low dose ...

However, new research from the University of Alabama at Birmingham found that the use of low-dose atropine eye drops was no better than placebo ...

Atropine drops fail to slow myopia in US children, study says - Healio

Very low-dose atropine eye drops no better than placebo for slowing myopia progression. ... no-better-placebo-slowing-myopia-progression.

Proof not positive yet on low-dose atropine for myopia in children

In the study released in July, 187 children ages 5 to 12 years were given either nightly atropine or placebo. The eye drops did not slow myopia ...

Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment ...

Interventions Once-daily placebo, low-dose atropine, 0.01%, or low-dose atropine, 0.02%, eye drops for 36 months. Main Outcomes and Measures The ...

Low-dose atropine drops, 0.01%, ineffective in stopping myopia ...

The use of low-dose atropine 0.01% to slow the progression of myopia in children is not supported by a recent randomized clinical trial ...

Low-Dose Atropine Eye Drops Flop for Slowing Kids' Myopia

At both the 24-month and 30-month marks, there were no significant differences between the atropine and placebo drops in regards to axial length ...

Low-Dose Atropine Eyedrops No Better Than Placebo for Slowing ...

Dr. Ticho is one of the lead authors of this important paper on treatment to slow development of myopia.

Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control

Importance: Controlling myopia progression is of interest worldwide. Low-dose atropine eye drops have slowed progression in children in East ...

Low-Concentration Atropine Eye Drops for Myopia Progression

The study firstly provided placebo-compared evidence of low-concentration atropine eye drops in myopia control. Furthermore, both efficacy and side effects ...

The Lowdown on Low-dose Atropine - Review of Optometry

After two years, the medication was stopped for one year, then any children demonstrating myopia progression of 0.50D or more in at least one ...

Growing Body of Research Suggests Low-Dose Atropine Can Help ...

New treatments are being developed to slow myopia in children, and potentially head off severe nearsightedness. Compelling evidence accumulated ...

The CHAMP study: safety and efficacy of low-dose atropine

The CHAMP study results showed low-dose atropine is safe and effective in slowing myopia progression in children over 3yr period.

Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control

Interview with Michael X. Repka, MD, MBA, author of Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical ...